Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines

Table 1 Cell line establishment protocol

Tumor ID	Direct cell line establishment	Cell line from xenograft	Corresponding xenograft	Paired B-LCL
HROC126	+	-	+	+
HROC239 T0 M1	-	+	+	+
HROC284Met	+	-	+	+

+: Positive; -: Negative; B-LCL: B-lymphoid cell line.

Table 2 Molecular characterization and mutational profile of rectal cancer cell lines

Cell line	CIMP-number	MSI-status	Ploidy status	TP53	APC	K-Ras	PIK3CA	BRAF	PTEN
HROC126	0	Mss	Aneuploid	Wt	Wt	Wt	Wt	Wt	Wt
HROC239 T0 M1	0	Mss	Aneuploid	Mut	Mut	Mut	Wt	Wt	Mut
HROC284Met	0	Mss	Aneuploid	Mut	Wt	Mut	Wt	Wt	Mut

Wt: Wildtype; Mut: Mutated; CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; Mss: Microsatellite stable.

Table 3 Half maximal inhibitory concentration values of antitumor drugs

Cell line	5-FU (μg/mL)	Irinotecan (μmol/L)	Oxaliplatin (μg/mL)
HROC126	0.42	0.72	0.3
HROC239 T0 M1	21	4.4	2.4
HROC284Met	7	4.3	0.68
Plasma levels (pharmacokinetic)	50	10	2

Values are given as mean, resulting from at least three independent experiments each performed in triplicates. 5-FU: 5-Fluorouracil.